The Latest Cardiac and Vascular News
MIAMI–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the late-breaking data from its Nanosecond PFA 360° Cardiac Catheter System first-in-human feasibility study, which data were recently presented […]
January 21, 2025 10:10 AM Eastern Standard Time TEMPE, Ariz.–(BUSINESS WIRE)–Aptyx, a leading global developer and manufacturer of complex components and devices for the life sciences, today announced the acquisition of the Charlotte, North Carolina facility of Medical Murray, which […]
[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received orphan drug status as a diagnostic for the management of AL amyloidosis in EU and US The…
MIAMI, Jan. 21, 2025 /PRNewswire/ — The Amavita Foundation, a leading organization dedicated to advancing cardiovascular health and supporting patients facing chronic limb-threatening ischemia (CLTI), is pleased to announce the appointment of Patty Vila to its Board of Directors. A…
LINCOLN, Neb., Jan. 21, 2025 /PRNewswire/ — Neogen® Corporation (NASDAQ: NEOG), an innovative leader in food security solutions, announced today the launch of Igenity® BCHF to improve overall bovine heart health standards. Bovine Congestive Heart Failure (BCHF) stands as a significant…
– Plans for filing an IND was agreed with the FDA in a recent meeting –
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that AMBER-HFpEF (Assessment of CK-586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF) is open to enrollment. AMBER-HFpEF is a Phase 2 randomized, placebo-controlled, double-blind, multi-center, dose-finding clinical trial of CK-4021586 (CK-586) in patients with symptomatic heart failure with preserved ejection fraction (HFpEF) with left ventricular ejection fraction (LVEF) ≥60%. CK-586 is a cardiac myosin inhibitor in development for the potential treatment of a subgroup of with symptomatic HFpEF patients with hypercontractility and ventricular hypertrophy.
SEOUL, South Korea, Jan. 21, 2025 /PRNewswire/ — AIRS Medical has finalized a landmark agreement with Starvision, a leading radiological practice network in Germany, to bring its advanced MRI reconstruction technology, SwiftMR, to diagnostic imaging practices in Hannover and Munich. This…
TAMPA, Fla., Jan. 20, 2025 /PRNewswire/ — Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the successful completion of patient enrolment in the SirPAD Trial, with over 1,250 patients now enrolled. The…
LIVERMORE, Calif., Jan. 17, 2025 /PRNewswire/ — Advanced Bifurcation Systems Inc. (ABS), a leader in innovative solutions for bifurcation lesions in coronary angioplasty, announces the successful closure of a $20.8 million Simple Agreement for Future Equity (SAFE) financing round. The…
![Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis](https://cardiacvascularnews.com/wp-content/uploads/2025/01/Life-molecular-imaging-e1737489511884-90x60.png)